TSR-033（Cat No.:I042210）is an investigational monoclonal antibody designed to target the immune checkpoint receptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is found on immune cells and plays a role in suppressing immune responses, allowing tumors to evade immune detection. By inhibiting TIGIT, TSR-033 aims to enhance T-cell activation and restore immune responses against cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors. TSR-033 is evaluated for safety, efficacy, and its potential as part of combination immunotherapies to improve patient outcomes.
